Novo Nordisk Juggles Promising Pill Rollout and Sobering Stock Metrics in Pivotal ADA Week
04.06.2026 - 03:13:17 | boerse-global.de
The Danish drugmaker enters one of its most consequential periods of the year with a mix of encouraging commercial news and deep stock market skepticism. While the launch of the oral Wegovy pill has surpassed expectations at home and is now testing international waters, the share price continues to languish in bear territory, leaving investors to weigh pipeline promise against relentless headwinds.
On the commercial front, momentum is building. Since Wegovy’s tablet form debuted in the US in January 2026, more than two million prescriptions have been written — roughly double internal forecasts. The oral version generated 2.3 billion Danish kroner in first-quarter sales, representing about 3% of group revenue. On June 3, Novo took the pill abroad for the first time, securing approval in the United Arab Emirates for both weight management and cardiovascular risk reduction, backed by the OASIS-4 trial showing an average 17% weight loss. A further boost comes from Medicare: starting July 1, 2026, eligible patients with obesity can access Wegovy through a new bridge program at a $50 monthly copay, a rare step by the US insurer to cover anti-obesity medications.
Yet the stock tells a different story. Shares change hands at around €36.40, down 42.6% over the past twelve months and 18.5% year-to-date. The relative strength index of 42.1 points to lingering weakness, and the price remains decisively below its 200-day moving average — though it has crept above the 50-day line, hinting at a fragile recovery. Goldman Sachs recently raised its price target from 263 to 305 kroner but kept a Neutral rating, signaling that valuation has become more palatable without warranting outright optimism. The bank’s caution reflects a broader reality: Novo’s command of the GLP-1 market is slipping in the US, where Eli Lilly has grabbed a leading share. Novo’s US market share for semaglutide stood at 37.4% in early June, and the company’s own 2026 guidance calls for adjusted revenue and profit growth of between minus 4% and minus 12% at constant exchange rates, weighed down by American pricing pressure and the most-favored-nations agreement.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Against this backdrop, the American Diabetes Association’s Scientific Sessions in New Orleans, running from June 5 to 8, take on outsized importance. Novo will present 40 scientific abstracts, with the spotlight on Phase 3 results from the REIMAGINE studies of CagriSema — a weekly injectable combining the amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide, already filed with the FDA in December 2025 with a decision expected by late 2026. Phase 2b data for Zenagamtide, a dual GLP-1/amylin agonist, will also be unveiled. Management has scheduled an R&D investor event for Sunday, June 7, streamed live from the conference, to underscore the pipeline’s potential to drive the next growth phase.
Adding to the complexity, Novo has been buying back shares to shore up confidence. A program of up to 15 billion kroner has so far seen nearly 17.9 million shares repurchased at an average price of 263.47 kroner, for a total outlay of roughly 4.7 billion kroner. Not all institutional holders are convinced: Peapack Gladstone Financial Corp cut its stake by 25.5% in the fourth quarter, leaving 73,091 shares valued at around $3.7 million.
With gross margins of 81% and net margins of 33%, Novo’s underlying profitability remains robust, but the market is demanding proof that the pipeline can reignite growth and counter the competitive pressure from Lilly. The ADA presentations beginning this weekend will either provide the catalyst investors are waiting for — or deepen the doubts that have pushed the stock to its current low.
Ad
Novo Nordisk Stock: New Analysis - 4 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
